Sentence examples similar to negative relapse from inspiring English sources

CD19 negative relapses were reported by several groups (Maude et al., 2014a; Lee et al., 2015a; Turtle et al., 2016a; Grupp et al., 2013; Pegram et al., 2015), in which the Upenn group showed the highest incidence of up to 60% (Ruella et al., 2016).

CR was observed in both patients and was ongoing in one patient at 11 months after treatment (Ongoing CR at 3 years post-CTL019 cell infusion has been described (Tasian and Gardner 2015)), while the other patient experienced a CD19-negative relapse 2 months post-CAR-T cell infusion.

Twenty of fifty patients with CR at day 28 had subsequently relapsed (relapse-free survival is 44% at 12 months), thirteen of whom experienced CD19-negative disease relapse, which should be the most frequent CD19-negative relapse in the available data to date (Maude et al., 2014a; Davila et al., 2014; Lee et al., 2015a, b; Turtle et al., 2016a; Park et al., 2015).

Although markers may act as useful flags for relapse, they do not remove the need for clinical and imaging assessment in view of the rate of marker-negative relapse.

However, suboptimal clinical outcomes have been associated with decreased expansion and persistence of adoptively transferred CAR T cells, antigen-negative relapses, and impairment by an immunosuppressive tumor microenvironment.

The first dataset, the Rotterdam cohort [ 32], represents 180 lymph node-negative relapse-free patients [GEO GSE2034] and 106 lymph node-negative patients that developed a distant metastasis.

Smear negatives, relapsed or failed treatment were excluded.

As far as we are aware, our study is the first adequately powered, randomized controlled trial investigating psycho-education delivered via booklets, internationally and in Arab speaking countries, assessing participants' knowledge of schizophrenia, and positive and negative symptoms, relapse and caregivers' burden of care and quality of life.

The demographics of those clinicians who were eligible and who completed the survey (n = 15, per country) are shown in Table  1.> -wrap-foot> aNumber of patients ALL acute lymphoblastic leukaemia, N/A not available, Ph Philadelphia negative, R/R relapsed or refractory The clinical criteria used to define relapsed or refractory disease were similar across the countries.

However, the other two patients who did not receive allo-HSCT experienced CD19-negative disease relapse at 3 and 5 months.

No patient with a negative scan relapsed within the median follow-up period of 63 weeks.